New Zealand: ANZMES

Our new ANZMES Charitable Trust website is now live, with clearer pathways, easier navigation, and dedicated spaces for the people we serve.


Here’s what’s new:
  • A Patient Hub with practical guidance, lived‑experience insights, and support pathways
  • A Clinician Hub with CME‑accredited education, clinical tools, and best‑practice guidance
  • A Research Hub showcasing New Zealand‑led studies, evidence summaries, and sector updates
  • A clearer focus on our three core mandates: Research, Representation, Education
  • A refreshed brand identity that reflects our national role and future direction

This redesign is part of our commitment to providing trusted, evidence‑based information for everyone affected by ME/CFS, Long COVID, and associated conditions.

Take a look around — we’d love to hear what you think.



 
Last edited by a moderator:
It's just a smorgasbord of misinformation. These people certainly do not represent me as a person with ME/CFS in New Zealand.


What is the Septad?
The “Septad” refers to a cluster of seven overlapping conditions often seen alongside ME and Long COVID — including dysautonomia, MCAS, hEDS, GI issues, autoimmune conditions, chronic viral reactivation, and neurologic structural issues. These conditions share autonomic, immune, and connective‑tissue features. Emerging research and clinical patterns are also associating other conditions with ME.

Learn about associated conditions

On prevalence, they are suggesting 1 in 30 people 'living with ME'

They are using the name ME

ME... affects the body’s ability to produce and use energy (impaired cellular energy production and metabolism).
We are not a regional support group — we work at the national and international level to inform, represent, educate, and advance research for people with ME and associated conditions.
ME has 100-200+ symptoms due to multiple body systems being impacted.

11: Should I try Low Dose Naltrexone (LDN) for my ME or fibromyalgia?​

Answered 18/03/2026
Low-Dose Naltrexone (LDN) has been used safely in low doses “off-label” for fibromyalgia for years with efficacy in pain management. Clinical studies suggest that 50–60% of patients may experience a significant reduction in pain.1 While the drug was originally developed at high doses (50mg) to treat addiction, at “low” doses it acts as an immune modulator and atypical anti-inflammatory that reduces pain and fights inflammation.

More recently it has been used in ME, although research results are mixed with some patients finding it helpful for pain or fatigue, while others report no effect.2 However, according to Griffith University research, laboratory trials have shown that LDN can restore specific cellular functions that are often impaired in ME patients.3

Research highlights several biological mechanisms that make LDN a unique treatment:

  • Restoring Cell Function: Griffith University conducted a world-first laboratory study finding that LDN restores the function of TRPM3 ion channels in natural killer cells.3 These channels regulate how calcium moves in and out of every cell, which is a process that is often seriously affected in ME.2
  • Rebound Effect: LDN briefly blocks opioid receptors, which triggers a “rebound effect” that causes the body to increase its production of natural endorphins and opioid receptors.3
  • Quieting Brain Inflammation: LDN “quietens down” overactive immune cells (microglia) in the brain. This reduces the release of pro-inflammatory cytokines that contribute to the “brain fog” and pain associated with these conditions.1,2

12 Is ME a Functional Neurological Disorder?​

Answered 23/12/2025
Functional Neurological Disorder (FND) – is a real condition, but some confuse correlation with causation because ME and FND have overlapping symptoms. This does not mean that ME is caused by FND. They are both complex neurological conditions, but they are distinct and require critically different management approaches. The consequences of mistaking ME for FND are profound and can worsen the condition, leading to significantly lower quality of life and diminished physical and cognitive capacities.

  • The Key Difference: FND is understood as an information processing problem within the brain affecting how the brain and body send and receive signals. There are no structural changes to the brain in FND.
    ME, however, is a complex, multi-system illness where the mandatory, hallmark symptom is Post-Exertional Malaise (PEM) which is a severe worsening of all symptoms after minimal physical, mental, sensory, or emotional exertion. Studies show notable structural changes in the brains of people with ME/.1 2 3 4 5
 
Sigh

None so deaf as those who won't hear

ANZMES have received plenty of constructive critiques of their current approach as well as plenty of suggestions for improvement. All to no avail

It's not that surprising I guess. They're collaborating with doctors and researchers sharing their views and most (all?) of their international counterparts are singing from the same song sheet as well. Plenty of mutual reinforcement to be had right there

The probably inevitable result: ANZMES are convinced they know best. They're certainly not listening to this random black bird that occasionally flaps about in the periphery making some annoying kraa kraa kraa noise (until it crashes, conveniently for them)

I really don't know how we get out of this maelstrom of misinformation and poor strategy in the short term. It's not just an ANZMES thing. Almost all our advocates worldwide seem to have either jumped or fallen in

Long term I'm pinning my hopes on rigorous research, ably supported by S4ME, but in the meantime I'm afraid we have to make do with Forget-ME-Not Wellness notebooks (ANZMES have a shop now)

/rant
 
This post by ANZMES was for Severe ME Day 2026 (couldn't find a posting date but I'm guessing August 8 or so?) but I just saw it now. Thanks to Tom Kindlon for posting this on Mastodon.

I have not read it myself, just sharing it here.


It includes a link to an ANZMES GP Guide for Severe ME:


There's also information about CME/CPD‑accredited training.
 
Talk by Em. Prof Tate at the last ANZMES AGM in August (not enough new content to warrant a thread I don't think)

Mostly talking about old data, mainly - I think - this CPET & epigenetics study (13min) and some talk about diagnostic tests (20min) which appeared to be referring to the same study but again, not sure

Some other snippets, without much detail given:
  • is trying to establish a Māori cohort (23min)
  • pilot genetic family risk signature study, ongoing (25min)
  • appears to now have a cohort of 52 cases to play with, previously they rarely got into double figures
  • some sort of genetics paper in the process of being published in Trends in Genetics(?), not clear to me what but sounded more like a review or hypothesis paper rather than new data
 
Back
Top Bottom